Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sale Of Lupus Drug License Option To Cephalon Sets Up Immupharma Business Strategy

This article was originally published in The Pink Sheet Daily

Executive Summary

U.K. biotech says partnership with French research institution, recent cash infusions leave it well-funded.

You may also be interested in...



Deals Of The Week: Wyeth/Santaris, Novartis/HHS, Cephalon/Ception ...

Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.

Deals Of The Week: Wyeth/Santaris, Novartis/HHS, Cephalon/Ception ...

Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.

Cephalon Option To Buy Biologics Firm Ception Gets The Ball Rolling For 2009, CEO Says

Look for Cephalon to “roll up” more assets this year while the market is good, CEO Baldino says at J.P. Morgan.

Related Content

Topics

UsernamePublicRestriction

Register

PS067068

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel